EA202191582A1 - CLEAVE BY MATRIX METAL PROTEASE AND CLEAVE BY SERINE OR CYSTEINE PROTEASE SUBSTRATES AND METHODS OF THEIR APPLICATION - Google Patents
CLEAVE BY MATRIX METAL PROTEASE AND CLEAVE BY SERINE OR CYSTEINE PROTEASE SUBSTRATES AND METHODS OF THEIR APPLICATIONInfo
- Publication number
- EA202191582A1 EA202191582A1 EA202191582A EA202191582A EA202191582A1 EA 202191582 A1 EA202191582 A1 EA 202191582A1 EA 202191582 A EA202191582 A EA 202191582A EA 202191582 A EA202191582 A EA 202191582A EA 202191582 A1 EA202191582 A1 EA 202191582A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- protease
- cleave
- substrate
- methods
- serine
- Prior art date
Links
Landscapes
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Изобретение в целом относится к полипептидам, которые содержат по меньшей мере первый расщепляемый фрагмент (CM1), который является субстратом для по меньшей мере одной матриксной металлопротеазы (MMP), и по меньшей мере второй расщепляемый фрагмент (CM2), который является субстратом для по меньшей мере одной сериновой протеазы (SP) или по меньшей мере одной цистеиновой протеазы (CP), к активируемым антителам и другим более крупным молекулам, которые содержат эти полипептиды, которые содержат по меньшей мере CM1, который является субстратом для по меньшей мере одной протеазы MMP, и по меньшей мере CM2, который является субстратом для по меньшей мере одной протеазы SP или по меньшей мере одной цистеиновой протеазы (CP), и к способам получения и применения этих полипептидов, которые содержат по меньшей мере CM1, который является субстратом для по меньшей мере одной протеазы MMP, и по меньшей мере CM2, который является субстратом для по меньшей мере одной протеазы SP или по меньшей мере одной цистеиновой протеазы (CP), при различных показаниях в терапевтических, диагностических и профилактических целях.The invention generally relates to polypeptides that contain at least a first cleavage fragment (CM1), which is a substrate for at least one matrix metalloprotease (MMP), and at least a second cleavage fragment (CM2), which is a substrate for at least at least one serine protease (SP) or at least one cysteine protease (CP), to activatable antibodies and other larger molecules that contain these polypeptides, which contain at least CM1, which is a substrate for at least one MMP protease, and at least CM2, which is a substrate for at least one SP protease or at least one cysteine protease (CP), and methods for the preparation and use of these polypeptides, which contain at least CM1, which is a substrate for at least one MMP protease, and at least CM2, which is a substrate for at least one SP protease or at least about DNA cysteine protease (CP), for various indications for therapeutic, diagnostic and prophylactic purposes.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862778062P | 2018-12-11 | 2018-12-11 | |
| PCT/US2019/064779 WO2020118109A2 (en) | 2018-12-06 | 2019-12-05 | Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202191582A1 true EA202191582A1 (en) | 2021-09-03 |
Family
ID=77912716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202191582A EA202191582A1 (en) | 2018-12-11 | 2019-12-05 | CLEAVE BY MATRIX METAL PROTEASE AND CLEAVE BY SERINE OR CYSTEINE PROTEASE SUBSTRATES AND METHODS OF THEIR APPLICATION |
Country Status (1)
| Country | Link |
|---|---|
| EA (1) | EA202191582A1 (en) |
-
2019
- 2019-12-05 EA EA202191582A patent/EA202191582A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017015468A2 (en) | serine protease cleavable and matrix metalloprotease cleavable substrates and methods of use thereof | |
| MX2021006429A (en) | Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof. | |
| NO20052096L (en) | Methods for forming and screening for altered specificity proteases. | |
| ES2372709T3 (en) | PROCEDURES FOR PROTEASES AND PROTEASES IDENTIFIED BY THE SAME PROCESSES. | |
| BR112019007977A2 (en) | compound, pharmaceutical composition, method of treating or preventing cancer, and use of a compound | |
| CL2018000226A1 (en) | Peptide mixture (divisional application 201601405) | |
| IS8343A (en) | Proteasome inhibitors and methods for using them | |
| BR112016017649A2 (en) | substrates for matriptase and plasminogen activator u and other cleavable portions and their methods of use | |
| ATE513917T1 (en) | BACTERIAL EXPRESSION OF PROTEASE INHIBITORS AND VARIANTS THEREOF | |
| ECSP077321A (en) | PROCESSES AND INTERMEDIARIES TO PREPARE INHIBITORS OF CYSTEINE PROTEASA | |
| CL2019002478A1 (en) | Formulation of monoclonal anti-vrs. | |
| BR112016002845A2 (en) | compositions and methods for treating complement-associated conditions | |
| BR112017019919A2 (en) | optical probes for matrix metalloproteinases | |
| WO2020030984A3 (en) | Compositions and methods for genome engineering with cas12a proteins | |
| DOP2019000215A (en) | HUMANIZED ANTIBODY TO TREAT OR PREVENT COGNITIVE DISORDERS, PROCESS TO PRODUCE IT, AND AGENT TO TREAT OR PREVENT COGNITIVE DISORDERS USING IT | |
| MX2014012285A (en) | Methods for treating or preventing influenza virus infection by administering a serine protease inhibitor. | |
| WO2017021004A8 (en) | Chromogenic and fluorogenic peptide substrates for the detection of serine protease activity | |
| EA201892051A1 (en) | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF MALIGNANT NON-FORMATION | |
| EA202191582A1 (en) | CLEAVE BY MATRIX METAL PROTEASE AND CLEAVE BY SERINE OR CYSTEINE PROTEASE SUBSTRATES AND METHODS OF THEIR APPLICATION | |
| WO2019173503A3 (en) | Serine protease inhibitor kazal (spik) compositions and methods | |
| AU2019269617A8 (en) | Compositions comprising PCSK9-binding molecules and methods of use | |
| WO2020264361A8 (en) | Circular strained zymogen compositions and methods of use | |
| DE60331414D1 (en) | AGGRECANASE 1 AND 2 PEPTIDE SUBSTRATES AND METHOD | |
| DE602006008751D1 (en) | SYNTHESIS OF PROTEASE INHIBITION PREPARATIONS | |
| AR120759A1 (en) | ANTI-CORONAVIRUS ANTIBODIES AND METHODS OF USE |